The ‘Pushmi-Pullyu’ of DNA REPAIR: Clinical Synthetic Lethality

Trends in Cancer

Volumn 2, Issue 11, 2016, Pages 646-656

  Ivy, S Percy ^a   de Bono, Johann ^b   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

DNA damage repair; DNA damage response; genomic instability; homologous recombination defects; mutational burden; synthetic lethality

Indexed keywords

DNA; ANTINEOPLASTIC AGENT;

DNA DAMAGE; DNA REPAIR; GENE TARGETING; LETHALITY; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; HUMAN; LETHAL MUTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR; HUMANS; SYNTHETIC LETHAL MUTATIONS;

EID: 85000950787     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.10.014     Document Type: Review

References (55)

1. 1 Kaelin, W.G. Jr., The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5 (2005), 689–698.
2. 2 McLornan, D.P., et al. Applying synthetic lethality for the selective targeting of cancer. N. Engl. J. Med. 371 (2014), 1725–1735.
3. 3 Dietlein, F., et al. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 30 (2014), 326–339.
4. 4 Lindahl, T., et al. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem. Sci. 20 (1995), 405–411.
5. 5 O'Connor, M.J., Targeting the DNA damage response in cancer. Mol. Cell 60 (2015), 547–560.
6. 6 Lindahl, T., Wood, R.D., Quality control by DNA repair. Science 286 (1999), 1897–1905.
7. 7 Willis, N.A., et al. Deciphering the code of the cancer genome: mechanisms of chromosome rearrangement. Trends Cancer 1 (2015), 217–230.
8. 8 Lofting, H., The Story of Doctor Dolittle: Being the History of His Peculiar Life at Home and Astonishing Adventures in Foreign Parts Never Before Printed. 1920, Yearling Books.
9. 9 Brown, E.J., Baltimore, D., ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14 (2000), 397–402.
10. 10 Hoeijmakers, J.H., Genome maintenance mechanisms for preventing cancer. Nature 411 (2001), 366–374.
11. 11 Williams, A.B., Schumacher, B., p53 in the DNA-damage-repair process. Cold Spring Harb. Perspect. Med., 6, 2016, a026070.
12. 12 Chen, Z., et al. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol. Cancer Ther. 2 (2003), 543–548.
13. 13 Nghiem, P., et al. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl. Acad. Sci. U.S.A. 98 (2001), 9092–9097.
14. 14 Wood, R.D., et al. Human DNA repair genes. Science 291 (2001), 1284–1289.
15. 15 Sancar, A., et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73 (2004), 39–85.
16. 16 Porro, A., Editorial: grappling with the multifaceted world of the DNA damage response. Front. Genet., 7, 2016, 91.
17. 17 Bartek, J., Lukas, J., DNA damage checkpoints: from initiation to recovery or adaptation. Curr. Opin. Cell Biol. 19 (2007), 238–245.
18. 18 Harper, J.W., Elledge, S.J., The DNA damage response: ten years after. Mol. Cell 28 (2007), 739–745.
19. 19 Cheung-Ong, K., et al. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem. Biol. 20 (2013), 648–659.
20. 20 Bryant, H.E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005), 913–917.
21. 21 Farmer, H., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005), 917–921.
22. 22 Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
23. 23 Swisher, S.G., et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91 (1999), 763–771.
24. 24 Glazer, P.M., et al. Hypoxia and DNA repair. Yale J. Biol. Med. 86 (2013), 443–451.
25. 25 Scanlon, S.E., Glazer, P.M., Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA Rep. 32 (2015), 180–189.
26. 26 Rottenberg, S., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 17079–17084.
27. 27 Fong, P.C., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361 (2009), 123–134.
28. 28 Kim, K.H., et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21 (2015), 1491–1496.
29. 29 Bitler, B.G., et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21 (2015), 231–238.
30. 30 Courjal, F., et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int. J. Cancer 69 (1996), 247–253.
31. 31 Hwang, H.C., Clurman, B.E., Cyclin E in normal and neoplastic cell cycles. Oncogene 24 (2005), 2776–2786.
32. 32 Keyomarsi, K., et al. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347 (2002), 1566–1575.
33. 33 Morgan, M.A., et al. Improving the efficacy of chemoradiation with targeted agents. Cancer Discov. 4 (2014), 280–291.
34. 34 Mueller, S., Haas-Kogan, D.A., WEE1 Kinase As a Target for Cancer Therapy. J. Clin. Oncol. 33 (2015), 3485–3487.
35. 35 Sarcar, B., et al. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol. Cancer Ther. 10 (2011), 2405–2414.
36. 36 Zhou, B.B., Bartek, J., Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer 4 (2004), 216–225.
37. 37 Pouliot, L.M., et al. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res. 72 (2012), 5945–5955.
38. 38 Rowley, R., et al. The wee1 protein kinase is required for radiation-induced mitotic delay. Nature 356 (1992), 353–355.
39. 39 Leijen, S., et al. Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy. J. Clin. Oncol., 33(Suppl.), 2015 abstr 2507.
40. 40 Oza, A.M., et al. An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer. J. Clin. Oncol., 33(Suppl.), 2015 abstr 5506.
41. 41 Timms, K.M., et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res., 16, 2014, 475.
42. 42 Lee, J.M., et al. CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer. Front. Oncol., 5, 2015, 123.
43. 43 Higuchi, T., et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol. Res. 3 (2015), 1257–1268.
44. 44 Malaquin, N., et al. DDR-mediated crosstalk between DNA-damaged cells and their microenvironment. Front. Genet., 6, 2015, 94.
45. 45 McGranahan, N., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
46. 46 Snyder, A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
47. 47 Tutt, A., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376 (2010), 235–244.
48. 48 Ledermann, J., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366 (2012), 1382–1392.
49. 49 Mateo, J., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373 (2015), 1697–1708.
50. 50 Pritchard, C.C., et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. NEJM 75 (2016), 443–453.
51. 51 Iyer, G., et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol. 31 (2013), 3133–3140.
52. 52 Ceccaldi, R., et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res. 75 (2015), 628–634.
53. 53 Abkevich, V., et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107 (2012), 1776–1782.
54. 54 Birkbak, N.J., et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2 (2012), 366–375.
55. 55 Telli, M.L., et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triplenegative breast cancer. Clin. Cancer Res. 22 (2016), 3764–3773.